New Zealand Pharmaceuticals and Healthcare Report Q4 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 75

BMI View: New Zealand's Pharmaceutical Management Agency (PHARMAC) will continue to leverage its

dominant position as a central procurer of drugs in the country to drive cost savings. While the high

standards used by the agency in its funding decisions will make the process difficult, PHARMAC does

acknowledge innovation as reflected by the expedient approval of Opdivo (nivolumab). This accentuates the

need for multinational drugmakers operating in New Zealand to ensure that their treatments substantially

improve healthcare outcomes.

Headline Expenditure Forecasts

? Pharmaceuticals: NZD1.42bn (USD1.1bn) in 2015 to NZD1.4bn (USD986mn) in 2016; 1.2% in local

currency terms and -1.8% in US dollar terms. Slight downward revision based on new data while US

dollar value is due to currency fluctuations of the New Zealand kiwi.

? Healthcare: NZD27.4bn (USD19.1bn) in 2015 to NZD28.4bn (USD19.22bn) in 2016; 3.6% in local

currency terms and 0.5% in US dollar terms.

New Zealand Pharmaceuticals and Healthcare Report Q4 2016

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (New Zealand 2014-2020) 7
SWOT 9
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (New Zealand 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020) 15
Prescription Drug Market Forecast 16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020) 17
Patented Drug Market Forecast 18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020) 19
Generic Drug Market Forecast 20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020) 21
OTC Drug Market Forecast 22
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020) 23
Pharmaceutical Trade Forecast 24
Table: Pharmaceutical Trade Data And Forecasts (New Zealand 2014-2020) 25
Table: Pharmaceutical Trade Data And Forecasts local currency (New Zealand 2014-2020) 25
Industry Risk Reward Index 26
Asia Pacific Risk/Reward Index - Q4 2016 26
New Zealand Risk/Reward Index 33
Rewards 33
Risks 33
Regulatory Review 35
Regulatory Development 35
Intellectual Property Issues 35
Pricing & Reimbursement Regime 36
Table: Funding decisions for July - September 2014 41
Market Overview 43
Healthcare Sector 43
Table: Healthcare Resources (New Zealand 2010-2015) 45
Table: Healthcare Activity (New Zealand 2010-2015) 45
Table: Healthcare Personnel (New Zealand 2010-2015) 45
Research & Development 46
Clinical Trials 47
Epidemiology 49
Competitive Landscape 52
Research-Based Industry 52
Table: Multinational Market Activity 53
Pharmaceutical Distribution 53
Pharmaceutical Retail Sector 54
Company Profile 56
Douglas Pharmaceuticals 56
New Zealand Pharmaceuticals 59
Pfizer New Zealand 62
Demographic Forecast 64
Table: Population Headline Indicators (New Zealand 1990-2025) 65
Table: Key Population Ratios (New Zealand 1990-2025) 65
Table: Urban/Rural Population & Life Expectancy (New Zealand 1990-2025) 66
Table: Population By Age Group (New Zealand 1990-2025) 66
Table: Population By Age Group % (New Zealand 1990-2025) 67
Glossary 69
Methodology 71
Pharmaceutical Expenditure Forecast Model 71
Healthcare Expenditure Forecast Model 71
Notes On Methodology 72
Risk/Reward Index Methodology 73
Index Overview 74
Table: Pharmaceutical Risk/Reward Index Indicators 74
Indicator Weightings 75

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (New Zealand 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (New Zealand 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (New Zealand 2014-2020)
Table: Funding decisions for July - September 2014
Table: Healthcare Resources (New Zealand 2010-2015)
Table: Healthcare Activity (New Zealand 2010-2015)
Table: Healthcare Personnel (New Zealand 2010-2015)
Table: Multinational Market Activity
Table: Population Headline Indicators (New Zealand 1990-2025)
Table: Key Population Ratios (New Zealand 1990-2025)
Table: Urban/Rural Population & Life Expectancy (New Zealand 1990-2025)
Table: Population By Age Group (New Zealand 1990-2025)
Table: Population By Age Group % (New Zealand 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators
  • Israel Pharmaceuticals and Healthcare Report Q1 2017
    Published: 30-Nov-2016        Price: US 1295 Onwards        Pages: 118
    BMI View: Israel will continue to be targeted by multinational drugmakers as a destination for innovative drug sales; however, their relative success will be limited by funding constraints towards the country's health services basket and the lack of transparency with new drug inclusions. An uptick in economic growth and an increase to government funding supports our moderate growth outlook for Israel's pharmaceuticals and healthcare sectors over the coming years. He......
  • Italy Pharmaceuticals and Healthcare Report Q1 2017
    Published: 30-Nov-2016        Price: US 1295 Onwards        Pages: 80
    BMI View: The rising demand for medicines for the treatment of cardiovascular diseases, gastric conditions, the nervous system and the respiratory system (the therapeutic areas that recorded the highest expenditure in 2015) and the government's aim in ensuring its population continues to access these medicines, will lead to complex pricing and reimbursement discussions, placing downward pressures on drugmaker revenue streams. Despite a long-term decline in the public expe......
  • Jordan Pharmaceuticals and Healthcare Report Q1 2017
    Published: 30-Nov-2016        Price: US 1295 Onwards        Pages: 84
    BMI View: Growth within Jordan's pharmaceutical market will be supported by a growing network of trade agreements and entry into new export markets. As a fall in domestic demand prompts expansion strategies, Jordanian drugmakers will continue to explore commercial opportunities outside of the traditional Middle Eastern pharmaceutical markets. The strengthening of pre-existing ties will support local drugmakers' attempts to boost their export potential and further trade wi......
  • Lebanon Pharmaceuticals and Healthcare Report Q1 2017
    Published: 30-Nov-2016        Price: US 1295 Onwards        Pages: 77
    BMI View: The ongoing Syrian civil war has had a substantial impact on Lebanon's healthcare service and finances, with a troubled political climate further exacerbating the crisis. On a positive note, the influx of international funds to help with the country's refugee surge has led to an increase in primary healthcare centres opening, providing greater access to the country's most vulnerable people. Over the long term, we expect a growing and ageing population, coupled w......
  • Mauritius Pharmaceuticals and Healthcare Report Q1 2017
    Published: 30-Nov-2016        Price: US 1295 Onwards        Pages: 53
    BMI View: Healthcare spending growth and a business-friendly policy environment will continue to create commercial opportunities for drugmakers and healthcare operators in Mauritius over the forecast period. Meanwhile, the outlook for a stronger integration between Mauritius and regional peers including India, Pakistan and the East African Community bodes well for Mauritius' efforts to gradually strengthen its position as a biomedicine manufacturing hub and medical touris......
  • Philippines Pharmaceuticals and Healthcare Report Q1 2017
    Published: 30-Nov-2016        Price: US 1295 Onwards        Pages: 98
    BMI View: Despite high enrolment numbers with the Philippine Health Insurance Corporation (PhilHealth), further reforms to the Philippines's healthcare system will be necessary for the country's universal healthcare scheme to galvanise the pharmaceutical and healthcare sector. Factors such as a lack of human resources, poor patient accessibility to clinics and hospitals and limited insurance coverage will all hold back growth in the healthcare sector. Headline Expen......
  • Poland Pharmaceuticals and Healthcare Report Q1 2017
    Published: 30-Nov-2016        Price: US 1295 Onwards        Pages: 73
    BMI View: The outlook for both Poland's pharmaceutical and healthcare markets will be driven by government reforms targeting greater access to healthcare. Over the short term, changes to reimbursement and co-payment exemptions will boost expenditure, while the change to a tax-based healthcare system will drive long-term growth. Headline Expenditure Projections ? Pharmaceuticals: PLN33.39bn (USD8.86bn) in 2015 to PLN34.79bn (USD8.56bn) in 2016; +4.2% in local c......
  • Romania Pharmaceuticals and Healthcare Report Q1 2017
    Published: 30-Nov-2016        Price: US 1295 Onwards        Pages: 78
    BMI View: In line with Romania's economic outperformance in Europe, the country's pharmaceutical and healthcare markets will see strong growth given increased consumer spending power and higher healthcare contributions. However, aggressive drug pricing regulations and cross-border negotiations on medicine pricing and procurement will limit revenue-earning opportunities. Headline Expenditure Projections ? Pharmaceuticals: RON14.94bn (USD3.73bn) in 2015 to RON15.90bn ......
  • Saudi Arabia Pharmaceuticals and Healthcare Report Q1 2017
    Published: 30-Nov-2016        Price: US 1295 Onwards        Pages: 87
    BMI View: Although issues pertaining to market access will continue to be of concern for multinational drugmakers, the Saudi Arabian pharmaceutical market will remain as one of the most commercially attractive in the Middle East and Africa region. The kingdom's young and growing population is a major draw for multinationals pharmaceutical companies, given that the Saudi Arabian drug market remains import-reliant. Furthermore, the kingdom's increasing focus on healthcare a......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs